Global Human Recombinant Insulin Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Human Recombinant Insulin Market Research Report 2024
Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.Recombinant human insulin has a significant advantage over insulin from other animal sources. Patients can better absorb human insulin.It is also easier to manage allergies related to insulin intake.
According to Mr Accuracy reports’s new survey, global Human Recombinant Insulin market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Human Recombinant Insulin market research.
Key manufacturers engaged in the Human Recombinant Insulin industry include Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon and Wanbang Biopharmaceuticals, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Human Recombinant Insulin were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Human Recombinant Insulin market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Recombinant Insulin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
![](http//localhost/mraccuracy/images/Market%20Recearch%20Graph.jpg)
Novo Nordisk
Eli Lilly and Company
Sanofi
Julphar Gulf Pharmaceutical Industries
Bioton
Gan & Lee Pharmaceuticals
Zhuhai United Laboratories
Biocon
Wanbang Biopharmaceuticals
Dongbao Enterprise Group
PeproTech
Segment by Type
Rapid-Acting Human Insulin
Regular (Short Acting) Insulin
NPH (Intermediate Acting) Insulin
Long-Acting Human Insulin
Premixed Human Insulins Insulin
Hospital
Retail Pharmacy
Online Pharmacies
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Human Recombinant Insulin report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source![](http://localhost/mraccuracy/images/About Report.webp)
According to Mr Accuracy reports’s new survey, global Human Recombinant Insulin market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Human Recombinant Insulin market research.
Key manufacturers engaged in the Human Recombinant Insulin industry include Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon and Wanbang Biopharmaceuticals, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Human Recombinant Insulin were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Human Recombinant Insulin market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Recombinant Insulin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
![](http//localhost/mraccuracy/images/Market%20Recearch%20Graph.jpg)
By Company
Novo Nordisk
Eli Lilly and Company
Sanofi
Julphar Gulf Pharmaceutical Industries
Bioton
Gan & Lee Pharmaceuticals
Zhuhai United Laboratories
Biocon
Wanbang Biopharmaceuticals
Dongbao Enterprise Group
PeproTech
Segment by Type
Rapid-Acting Human Insulin
Regular (Short Acting) Insulin
NPH (Intermediate Acting) Insulin
Long-Acting Human Insulin
Premixed Human Insulins Insulin
Segment by Application
Hospital
Retail Pharmacy
Online Pharmacies
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Human Recombinant Insulin report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
![](http://localhost/mraccuracy/images/About Report.webp)